Indian clinical practice consensus guidelines for the management of very advanced head-and-neck squamous cell carcinoma: Update 2022
Year: 2024
Type: article
Abstract: The management of recurrent or metastatic head-and-neck cancers is evolving. Promising novel immunotherapies and targeted therapies have led to a paradigm shift in the management of very advanced disease. Single-agent systemic therapy including cisplatin/carboplatin/paclitaxel/docetaxel/5-florouracil/methotrexate/cetuximab/gemcitabine/capecitabine or combination chemotherapy may be considered. Immunotherapy alone or in combination with chemotherapy has improved survival and should be considered. Oral metronomic chemotherapy with or without immunotherapy also improves oncologic outcomes. The challenges associated with the disease may be resolved by using an integrated approach of combining locoregional and systemic therapies. Salvage treatments like re-radiation or surgery are useful for the management of locoregional recurrences.
Authors: Vanita Noronha, Kumar Prabhash, K Govind Babu, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Anil K. Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayyar, Vijay M. Patil, Vishal Rao, Vikas Roshan, G.K. Rath
Institutions: Tata Memorial Hospital, HCG Cancer Hospital, Healthcare Global Enterprises, Mazumdar Shaw Medical Centre, Fortis Memorial Research Institute, Clatterbridge Cancer Centre NHS Foundation Trust, Indraprastha Apollo Hospitals, Rajiv Gandhi Cancer Institute and Research Centre, Sri Shankara Cancer Hospital and Research Center, Christian Medical College, Vellore, Max Super Speciality Hospital, P. D. Hinduja Hospital and Medical Research Centre, HCG Cancer Centre, All India Institute of Medical Sciences
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4390919882